RESEARCH REPORT Dave Levitan The combination of whole-brain radiation therapy and the EGFR inhibitor erlotinib showed a promising response rate and was well tolerated in a new phase II trial of patients with brain metastases from non-small-cell lung cancer.
REVIEW ARTICLE Elgene Lim, Nancy U. Lin;ONCOLOGY Vol. 26 No. 7 This review will focus on the breast cancer subtypes with the highest incidence of breast cancer brain metastases and will characterize differences in the clinical behavior of brain metastases that arise from these different subtypes.
We review the current data regarding the prognostic and predictive value of IDH mutation and 1p/19q codeletion in gliomas. We also discuss possible management algorithms using these biomarkers to tailor surgical and adjuvant therapy for specific diffuse gliomas.
• Molecular Classification of Diffuse Gliomas
The development of metastatic disease in patients with paraganglioma is an unusual and challenging event. This case report and review describes the specific features of this disease and the multiple therapeutic options.
• An Uncommon Manifestation of an Uncommon Disease
A healthy 24-year-old male presented with a history of several months of poorly localized headaches and blurred vision. MRI of the brain demonstrated a multi-lobulated mass. Based on the radiographic appearance of the mass, what is the most likely diagnosis?